# Efficacy, Safety, Preference and Response Duration of Clobex® Spray and Taclonex® Ointment in Psoriasis

> **NCT00437255** · PHASE4 · COMPLETED · sponsor: **Galderma R&D** · enrollment: 122 (actual)

## Conditions studied

- Plaque Psoriasis

## Interventions

- **DRUG:** Clobetasol Propionate, 0.05%
- **DRUG:** Calcipotriene and betamethasone dipropionate ointment

## Key facts

- **NCT ID:** NCT00437255
- **Lead sponsor:** Galderma R&D
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** 2007-06
- **Final completion:** 2007-06
- **Target enrollment:** 122 (ACTUAL)
- **Last updated:** 2022-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00437255

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00437255, "Efficacy, Safety, Preference and Response Duration of Clobex® Spray and Taclonex® Ointment in Psoriasis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00437255. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*